.Pharmacolibrary.Drugs.ATC.A.A02BA02

Information

Ranitidine is a histamine H2-receptor antagonist that was widely used to reduce stomach acid production for the treatment of peptic ulcer disease, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome. Its use has been greatly reduced and withdrawn in many countries due to concerns over NDMA contamination and related potential carcinogenicity.

Pharmacokinetics

PK parameters reported for healthy adult volunteers after single oral dose administration.

References

1. Florian, J, et al., & Strauss, DG (2021). Effect of Oral Ranitidine on Urinary Excretion of N-Nitrosodimethylamine (NDMA): A Randomized Clinical Trial. JAMA 326(3) 240–249. DOI:10.1001/jama.2021.9199 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34180947

2. James, LP, et al., & Argao, EA (1999). The pharmacokinetics of oral ranitidine in children and adolescents with cystic fibrosis. Journal of clinical pharmacology 39(12) 1242–1247. DOI:10.1177/00912709922012042 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10586389

3. Castañeda-Hernández, G, et al., & Hong, E (1996). Pharmacokinetics of oral ranitidine in Mexicans. Archives of medical research 27(3) 349–352. PUBMED:https://pubmed.ncbi.nlm.nih.gov/8854394

Revisions

• 06/2025 initial generated model